NASOPHARYNGEAL CANCINOMA (NPC)

This early-phase trial is testing a new approach for people with head and neck cancer that has returned or spread after standard chemotherapy. The treatment combines a gene therapy injection (EDS01) given directly into a tumor with an immunotherapy drug (toripalimab) given throug…

This study tests a new antibody called HMBD-001 combined with two existing cancer drugs (cetuximab and docetaxel) in people with advanced squamous cell cancers of the lung, head and neck, esophagus, cervix, or skin. The goal is to see if the combination is safe and can shrink tum…

This Phase 2 trial is testing whether adding low-dose radiotherapy to a standard chemotherapy regimen (gemcitabine and cisplatin) plus the immunotherapy drug toripalimab can help control recurrent or metastatic nasopharyngeal carcinoma. About 55 adults aged 18-65 with confirmed n…

This study tests a combination of three drugs—an EGFR antibody, a PD-1 inhibitor, and chemotherapy—in people whose nasopharyngeal cancer has returned or spread. The goal is to see if this mix can slow or stop the cancer from growing. About 148 adults aged 18-75 who have not had p…

This study tests a drug called becotatug vedotin in people with advanced nasopharyngeal cancer whose tumors didn't shrink enough after standard chemo-immunotherapy. About 59 adults will receive the drug during and after radiation therapy. The goal is to see if this approach can p…

This phase 3 trial is testing whether giving a lower dose of radiation to low-risk areas around the main tumor works as well as the standard higher dose for nasopharyngeal cancer. The study plans to enroll 700 people aged 18-70 with newly diagnosed, non-spreading cancer. The goal…

This phase 2 trial tests whether adding low-dose radiation to standard chemoimmunotherapy can better control liver tumors in people with nasopharyngeal carcinoma that has spread to the liver. The study will enroll 26 adults aged 18 to 70. Participants will receive low-dose radiat…

This phase II trial is testing whether adding the immunotherapy drug Toripalimab to different platinum-based chemotherapy regimens, followed by standard chemoradiotherapy, can improve outcomes for people with locally advanced nasopharyngeal cancer. About 243 participants will be …

This study looks at whether using only targeted radiation (IMRT) can effectively control stage IB nasopharyngeal cancer in patients without high-risk features. About 169 adults aged 18-70 with newly diagnosed, early-stage disease will be followed to see how many remain cancer-fre…

This phase 3 trial is testing whether proton radiation therapy plus carbon ion therapy works as well as standard photon radiation plus carbon ion for newly diagnosed nasopharyngeal carcinoma. About 470 participants will be randomly assigned to one of the two radiation types. The …

This phase 3 trial tests whether adding immunotherapy to standard treatment can improve outcomes for people with advanced nasopharyngeal cancer. About 802 participants will be split into low-risk and high-risk groups to see if personalized treatment can reduce side effects and pr…

This phase 3 trial tests whether Houyanqing Oral Liquid, a Chinese herbal mix, can prevent or reduce severe mouth sores caused by radiation therapy in 386 nasopharyngeal cancer patients. Participants take the liquid four times daily during radiation, alongside standard care. The …

This observational study is testing whether a new tool called RAIRI can better identify which patients with nasopharyngeal cancer might benefit from additional therapy after standard chemoradiation. About 900 adults with non-metastatic disease will be followed to see if the RAIRI…

This international study aims to improve how doctors stage nasopharyngeal cancer by collecting data from 5,000 patients across multiple countries. Researchers will use this information to refine the TNM staging system and combine it with other factors like biomarkers. The goal is…

This study enrolls 500 adults with nasopharyngeal carcinoma (stage I-III) who are receiving chemoradiotherapy with either proton or photon radiation. Researchers will collect imaging scans and blood samples to find markers that predict how well the cancer responds, side effects, …